-
PUBLICATION
2023.09.28
SMC is proud to announce that Dong-A ST Co., Ltd. (KOR) has published the results of their study using our pre-clinical services with the STAM™ mice in Biomed Pharmacother.
-
NEWS RELEASE
2023.09.22
The U.S. FDA has granted Breakthrough Therapy Designation (BTD) for 89bio, Inc.'s pegozafermin, a new drug candidate for non-alcoholic steatohepatitis (NASH).
-
UPCOMING EVENTS
SMC at BioJapan 2023 in October!
2023.09.15
We are pleased to announce that SMC Laboratories will be attending the BioJapan 2023 from October 11th (Wed) to 13th (Fri).
-
UPCOMING EVENTS
SMC attend The Digital Partnering in BioPharm America!
2023.09.08
We are pleased to announce that SMC Laboratories will be attending the BioPharm America Partnering Event from September 19th (Tue) to 20th (Wed).
-
PRODUCTS AND SERVICES
Acute Liver Failure Mouse Model Lineup
2023.08.30
Acute liver failure (ALF) carries a high mortality of approximately 40%, which is caused by virus infections (hepatitis A, B and E), drug-induced liver injury (acetaminophen/paracetamol) or autoimmune hepatitis. ALF exhibits symptoms of severe injury such as destruction of hepatocytes or decrease in liver function due to massive necrosis and inflammation.
-
PUBLICATION
2023.08.22
We are pleased to introduce a study on non-alcoholic steatohepatitis (NASH) may promote the development and exacerbation of psoriasis in STAM™ mice.
-
NEWS RELEASE
Announcement of webinar 【New NAFLD nomenclature ~Redefining the NAFLD/NASH mouse model~】
2023.08.16
Today, we are excited to invite you to join our Webinar that will be taking place on August 18th from 9:30 AM (JST).
-
NEWS RELEASE
Redefinition from NAFLD/NASH to MASLD/MASH
2023.08.09
The American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL) and the Asociacion Latinoamericana para el Estudio del Higado (ALEH) have collaborated to present a statement on disease definitions, names and diagnostic methods for nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH).
-
NEWS RELEASE
STAM™ Mice Is The Best NASH model For Microbiome Therapeutics Study
2023.08.02
We are pleased to introduce the development of drugs for non-alcoholic steatohepatitis (NASH) focusing on the gut microbiome and overview of studies using our STAM™ mice.
-
NEWS RELEASE
World Hepatitis Day 2023 ~ One life, one liver ~
2023.07.26
In recognition of July 28th being World Hepatitis Day, we here at SMC thought it might be a good idea to help everyone around the globe have a deeper understanding of hepatitis, so please read on if you would like to learn more.
-
UPCOMING EVENTS
SMC attend Digital partnering events 【Bio Asia-Taiwan 2023】!
2023.07.19
We are pleased to announce that SMC Laboratories will be virtually attending the BIO One-on-One Partnering™ in Bio Asia-Taiwan 2023 from July 26th to 30th.
-
PUBLICATION
2023.07.12
Please take a look at published study focusing on intracellular iron metabolism and mitophagy as therapeutic targets for hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH).
